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Plasma cathepsin D correlates with 
histological classifications of fatty 
liver disease in adults and responds 
to intervention
Sofie M. A. Walenbergh1, Tom Houben1, Sander S. Rensen1, Veerle Bieghs1, Tim Hendrikx1, 
Patrick J. van Gorp1, Yvonne Oligschlaeger1, Mike L. J. Jeurissen1, Marion J. J. Gijbels1, 
Wim A. Buurman1, Anita C. E. Vreugdenhil1, Jan Willem M. Greve2, Jogchum Plat1, 
Marten H. Hofker3, Satish Kalhan4, Jussi Pihlajamäki5,6, Patrick Lindsey1, Ger H. Koek7 & 
Ronit Shiri-Sverdlov1
Non-alcoholic steatohepatitis (NASH) is characterized by liver lipid accumulation and inflammation. 
The mechanisms that trigger hepatic inflammation are poorly understood and subsequently, no specific 
non-invasive markers exist. We previously demonstrated a reduction in the plasma lysosomal enzyme, 
cathepsin D (CatD), in children with NASH compared to children without NASH. Recent studies have 
raised the concept that non-alcoholic fatty liver disease (NAFLD) in adults is distinct from children due 
to a different histological pattern in the liver. Yet, the link between plasma CatD to adult NASH was 
not examined. In the current manuscript, we investigated whether plasma CatD in adults correlates 
with NASH development and regression. Biopsies were histologically evaluated for inflammation and 
NAFLD in three complementary cohorts of adults (total n = 248). CatD and alanine aminotransferase 
(ALT) were measured in plasma. Opposite to our previous observations with childhood NASH, we 
observed increased levels of plasma CatD in patients with NASH compared to adults without hepatic 
inflammation. Furthermore, after surgical intervention, we found a reduction of plasma CatD compared 
to baseline. Our observations highlight a distinct pathophysiology between NASH in children and 
adults. The observation that plasma CatD correlated with NASH development and regression is 
promising for NASH diagnosis.
The current obesity epidemic is paralleled by an increasing prevalence of non-alcoholic steatohepatitis (NASH). 
NASH is characterized by hepatic lipid accumulation (steatosis) and inflammation. While steatosis itself is gener-
ally considered benign and reversible, the presence of inflammation will eventually set the stage for further liver 
damage, including fibrosis, cirrhosis and liver cancer1,2. Currently, elevations in plasma alanine transaminase 
(ALT), a liver enzyme, are the primary clinical abnormality detected in NASH patients. When hepatocellular 
injury is present, this liver enzyme is released into the circulation. Although ALT is used as a tool for the routine 
diagnosis of NASH, it lacks specificity and sensitivity to distinguish between NASH and steatosis3,4. In order to 
improve non-invasive diagnosis of NASH, it is of clinical relevance to investigate novel underlying mechanisms 
during NASH pathophysiology. Although several processes have been identified that participate in the develop-
ment of hepatic inflammation, the actual mechanisms for the inflammatory response remain uncertain.
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We previously demonstrated a clear and direct association between hepatic inflammation and lysosomal cho-
lesterol accumulation inside Kupffer cells (KCs) of low-density lipoprotein receptor knockout (Ldlr−/−) mice fed 
a high-fat, high-cholesterol diet5–7. In accordance with our observation in mice, cholesterol-containing KCs were 
also demonstrated recently in livers of NASH patients8. The occurrence of lysosomal cholesterol accumulation 
has been shown to induce disturbances in the lysosomal (enzyme) trafficking pathway9,10. In line, we previously 
detected modified levels of the lysosomal enzyme cathepsin D (CatD) in the plasma of children with NASH com-
pared to children without hepatic inflammation11.
Recent studies have raised the concept that non-alcoholic fatty liver disease (NAFLD) in children and adults 
is distinct due to differences in the histological pattern in the liver as well as pathological characteristics of the 
disease12–15. Thus far, the relationship between plasma CatD and adult NASH has not been explored. Therefore, as 
a follow-up study from our data in children, we investigated in the current paper whether plasma CatD in adults 
correlates with the development and regression of NASH.
Here, we observed in three complementary cohorts of adults (average age > 40 years), with an average obese 
body mass index (BMI) of > 30 kg/m2, that plasma CatD is significantly increased along the development of 
NASH. As the plasma CatD levels in adults with NASH were the opposite of those previously found in children 
with NASH11, we point toward the existence of a potential different pathophysiology between NASH in children 
and adults. Our data further show that CatD responds to surgical intervention, which underlines the potential 
clinical relevance and diagnostic value of plasma CatD in the context of NASH.
Methods
Human cohorts; Cleveland cohort, Maastricht cohort and the Kuopio cohort. The design of this 
study includes three adult cohorts. All three cohorts demonstrated a similar adult age group (average age > 40 
years) and a similar average obese BMI (average BMI > 30 kg/m2). Across the three cohorts, all liver biopsies were 
histologically classified for NAFLD/NASH according to the criteria of Brunt and/or Kleiner, which includes stea-
tosis, ballooning, lobular inflammation and portal inflammation16,17.
The Cleveland cohort consists of NASH patients after the detection of abnormal plasma ALT values. The 
second and third population (the Maastricht and Kuopio cohort, respectively) include obese patients that are 
unselected for ALT, i.e., biopsies were taken during bariatric surgery regardless of their ALT levels. Patients from 
these cohorts are considered to have a wide spectrum of fatty liver diseases, including early stages.
Definition Cleveland cohort. A total of 127 adults (average age > 40 years) with an average obese 
BMI > 30 kg/m2 were included, of which 43 had biopsy-proven NASH. Subjects with NAFLD were recruited 
from the metabolic clinics of the Cleveland Clinic and MetroHealth Medical Center in Cleveland, OH. Excluding 
criteria, the procedure of obtaining and scoring of liver biopsies as well as blood sampling of this NASH Cleveland 
cohort have been described previously18–20. See Supplementary Table S1 for the patient characteristics of the 
Cleveland cohort.
Definition Maastricht cohort. 47 obese adult patients (average BMI > 30 kg/m2, average age > 40 years), 
undergoing bariatric surgery at the Maastricht University Medical Center or at the Atrium Medical Center 
Parkstad, Heerlen, the Netherlands, were included in the study. Excluding criteria, the procedure of obtain-
ing liver biopsies and blood sampling of this Maastricht obese cohort has been described previously21,22. See 
Supplementary Table S2 for the population characteristics of the Maastricht cohort. Liver biopsies were evaluated 
by a trained pathologist, according to the criteria of Brunt17 and Kleiner20 and graded for severity from NASH 
grade 1 (early-stage), to NASH grade 3 (late-stage) (see Supplementary Table S3).
Definition Kuopio cohort. All patients undergoing obesity surgery in Kuopio University Hospital are 
recruited into our ongoing study investigating metabolic consequences of obesity surgery (Kuopio Obesity 
Surgery Study)23,24. The study group included 74 obese adult subjects (average BMI > 30 kg/m2, average age > 40 
years), who were accepted for Roux-en-Y gastric bypass (RYGB) operation over the years 2005–2010. See 
Supplementary Table S4 for the general population characteristics at the start of intervention. Excluding criteria, 
the procedure of obtaining and scoring of the liver biopsies, and blood sampling of the Kuopio obese cohort has 
been described previously23–25.
Use of human subjects. With regard to the Cleveland cohort, the methods in this study were carried out in 
accordance with approved guidelines by the Institutional Review Boards at the Cleveland Clinic and MetroHealth 
Medical Center and was conducted according to the relevant guidelines of the protocol. For the Maastricht cohort, 
the study was carried out in accordance with the approved guidelines by the Medical Ethical Committees of both 
the Maastricht University Medical Centre and the Atrium Medical Centre Parkstad and conducted in accordance 
with the revised version of the Declaration of Helsinki (October 2008, Seoul). For the Kuopio cohort, the study 
protocol was carried out in accordance with approved guidelines by the Ethics Committee of the Northern Savo 
Hospital District (54/2005, 104/2008 and 27/2010), and it was performed according to the Helsinki Declaration. 
Written informed consent was obtained from all the subjects.
Human cathepsin D enzyme-linked immunosorbent assay. Plasma samples were diluted and CatD 
levels were determined by the CatD enzyme-linked immunosorbent assay according to the manufacturers’ proto-
col (Uscn Life Science Inc, Wuhan, China). The detection limit ranges approximately from 46.88 to 3,000 pg/ml. 
Coefficients of variation (CV%) for intra- and inter assays are < 10 and < 12% respectively. CatD measurements 
were performed blinded to the histology findings of the study participants.
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Immunohistochemistry. Bone marrow-derived macrophages. Bone marrow-derived macrophages 
(BMDMs) were isolated as described previously26. Cells were grown in 12-well plates (Greiner Bio-One) on cov-
erslips (Ø 20 mm; Thermo Scientific). BMDMs were washed twice with PBS and fixed with 4% paraformalde-
hyde for 15 min at room temperature. Fixed BMDMs were stored at 4 °C in PBS-NaN3 (0.03%) or washed three 
times with PBS− /− (Gibco) and directly used for immunocytochemistry. Subsequently, cells were permeabilized 
(0.1% Triton X-100 and 0.2% BSA in PBS) for 15 min and blocked (2% BSA-PBS) for 30 min at room tempera-
ture. Primary and secondary antibodies (2% BSA-PBS) were incubated for 1 h at room temperature. Coverslips 
were washed and mounted onto glass slides using DABCO-glycerol medium (Sigma-Aldrich) containing DAPI 
(1:10,000; Sigma-Aldrich) in order to counterstain nuclei. The following antibodies were used: goat anti-mouse 
CatD antibody (1:100, AF1029, R&D systems), rabbit anti-mouse lysosome-associated membrane protein-1 
(LAMP-1) antibody (1:200, Ab24170, Abcam), donkey anti-goat IgG NorthernLights (NL)557–conjugated anti-
body (1:200; NL001, R&D systems), goat anti-rabbit Alexa488 (1:200; Invitrogen). Cells were imaged using a 
Leica TCS SPE confocal laser scanning microscope (Leica Microsystems GmbH) equipped with an air-cooled 
argon-krypton mixed gas laser, using oil immersion objectives. ImageJ software was used to process and analyze 
the images.
Liver biopsy specimens. Immunohistochemistry for CatD was performed on paraffin-embedded liver sections 
originating from the Maastricht cohort. Sections were deparaffinized in xylene and ethanol and rehydrated in 
water. Antigen retrieval was achieved by incubating sections in 10 mM sodium citrate buffer in 0.05% Tween20, 
pH 6.0, at 95 °C. After cooling down, sections were quenched in hydrogen peroxide (3%) to suppress endogenous 
peroxidase activity. Prior to incubation with the first antibody, slides were first incubated with 1 × PBS plus an 
amplification step: 1:5 Avidin D Block solution followed by an incubation step with Biotin Block solution 1:5 in 
1 × PBS (Avidin/Biotin Blocking kit, SP-2001, Vector Laboratories, Burlingame, CA, USA). Sections were then 
incubated overnight at 4 °C with the primary CatD antibody (Cell Signaling Technology, no. 2284, Danvers, 
MA, USA; [1:50]) dissolved in 1 × PBS containing 0.05% Tween20. As negative controls sections were incu-
bated without primary antibody. Incubation with the second antibody for biotinylated donkey anti-rabbit IgG 
(Jackson ImmunoResearch Laboratories, West Grove, PA; [1:50]) was carried out in 1 × PBS containing 0.05% 
Tween20 for 30 min. Afterwards the slides were washed and incubated for an additional amplification step in 
1 × PBS + 1:50 Avidin D solution + 1:50 Biotin solution (Vectastain Elite ABC kit, PK-6100, Vector Laboratories, 
Burlingame, CA, USA). Then, 13-amino-9-ethylcarbazole (AEC) was applied using an AEC Peroxidase Substrate 
kit (Vector Laboratories, SK-4200, Burlingame, CA, USA) and haematoxylin for nuclear counterstaining. Sections 
were enclosed with Faramount aqueous mounting medium. Pictures were taken with a Nikon DMX1200 digital 
camera and ACT-1 version 2.63 software (Nikon Instruments Europe, Amstelveen, the Netherlands).
Statistical analysis. The data were analysed by performing two-tailed non-paired t-tests using GraphPad 
Prism for comparing the different groups. The data were expressed as mean ± SEM and considered significant at 
p < 0.05. The diagnostic accuracy of the combination ALT with CatD was calculated as described previously11.
Results
General population characteristics of the Cleveland cohort. ALT was significantly higher in 
patients with hepatic inflammation compared to their age- and gender-matched control subjects (p < 0.001) 
(see Supplementary Table S1). BMI, low-density lipoprotein (LDL), triglycerides and aspartate aminotransferase 
(AST) were all increased in subjects scored for hepatic inflammation compared to their matched controls. In 
line, plasma high-density lipoprotein (HDL) and the AST/ALT ratio were reduced in the group with hepatic 
inflammation.
Elevated CatD levels in plasma of patients with hepatic inflammation. First, CatD and ALT were 
measured in plasma of the Cleveland cohort. We found a significant increase of CatD in relation to liver biopsies 
of patients that demonstrate inflammation, compared to those without hepatic inflammation (No inflammation 
vs. inflammation: p < 0.001) (Fig. 1A). Next, we investigated the correlation between plasma ALT and CatD. 
Plasma CatD demonstrated a strong positive correlation with ALT (Pearson’s r = 0.57, p < 0.001) (Fig. 1B). These 
results suggest that plasma CatD levels are linked to the pathogenesis of NASH.
Population characteristics of the Maastricht cohort. To test whether plasma CatD is elevated 
already during early-stage of NASH, we used the Maastricht cohort consisting of patients with a wide range 
of fatty liver disease. Clinical characteristics of the patient population from this cohort are presented in 
Supplementary Table S2. The BMI from the cohort tested, ranged from 30.7 to 73.6 kg/m2 with an overall average 
of 46.7 kg/m2. The average plasma levels of ALT and AST were significantly higher in NASH patients as compared 
to subjects with a healthy liver (p = 0.018 and p = 0.019 respectively). Patients in the NASH group were signif-
icantly older compared to patients with a healthy liver (p = 0.021) and to those who had steatosis (p = 0.049). 
Importantly, there was no difference with respect to all other parameters (i.e., BMI, plasma total cholesterol, HDL, 
LDL, triglycerides and the AST/ALT ratio). Liver specimens of 27 NASH patients were histologically classified 
according to the scoring systems of Brunt and Kleiner. Most NASH subjects (14 out of 27) included displayed mild 
NASH (grade 1), as summarized in Supplementary Table S3. The majority of NASH patients showed steatosis 
score 2, ballooning score 1, lobular inflammation score 1, and no or little fibrosis.
Plasma CatD distinguishes NASH patients from subjects without hepatic inflammation and 
correlates with histological classifications of NAFLD. The level of plasma CatD was significantly 
higher in subjects with NASH compared to individuals with either simple steatosis or a healthy liver (NASH vs. 
normal: p = 0.031; NASH vs. steatosis: p = 0.0065) (Fig. 2A). More importantly, patients with a mild score for 
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NASH grade, i.e., grade 1, showed an increase in plasma CatD compared to patients without NASH (p = 0.0018) 
(Fig. 2B). The same significant trend holds true with respect to lobular inflammation, where CatD levels were 
already increased with mild disease as observed for NASH grade 1 (p = 0.0295) (Fig. 2C). In addition, CatD 
was strongly elevated upon mild steatosis, i.e., score 1, compared to patients without steatosis (p = 0.019), and 
decreased upon severity of steatosis (Fig. 2D). Similar to NASH grade, lobular inflammation and steatosis, 
CatD was primarily elevated upon mild fibrosis (score 1 and 2) compared to patients that did not show fibrosis 
(p = 0.002 and p = 0.019, respectively) (Fig. 2E). Moreover, total cholesterol levels correlated with plasma CatD 
(Fig. 2F). In summary, the plasma levels of the lysosomal enzyme CatD are increased in plasma of patients with 
NASH compared to the patients with a normal liver phenotype or steatosis alone. These data also suggest that 
plasma CatD correlates specifically with NAFLD severity, already from the early phase, and to cholesterol levels.
In contrast to ALT, CatD correlates with early stages of NASH. Currently, plasma ALT is the most 
common diagnostic tool in the clinic to detect hepatocellular injury during NASH. Significantly increased ALT 
levels were observed in patients with NASH and steatosis (NASH vs. normal: p = 0.018; steatosis vs. normal: 
p = 0.019) (Fig. 3A). While plasma CatD could differentiate NASH from steatosis, there was no difference in ALT 
concentrations between livers with NASH and steatosis, indicating that CatD correlates better with the spectrum 
of NAFLD than ALT. Moreover, ALT was only increased upon more advanced degrees of hepatic inflammation 
(NASH grade 2 vs. grade 0: p = 0.003; NASH grade 3 vs. grade 0: p < 0.001) (Fig. 3B), whereas CatD demonstrated 
to be elevated already during mild NASH (NASH grade 1). Plasma CatD was significantly higher in the early 
degrees of steatosis, lobular inflammation and fibrosis, whereas this was not true for ALT (Fig. 3C–E). A corre-
lation was found between CatD and total cholesterol, whereas no similar correlation could be detected for ALT 
(Fig. 3F). Thus, in contrast to ALT, CatD was elevated upon early NAFLD severity and could distinguish NASH 
from steatosis in adult subjects with obesity.
Potential clinical significance of using plasma CatD as an additional non-invasive screening method 
for NASH. Since our results suggest a strong association between increased plasma CatD and early-stage 
NASH, we next investigated the potential significance of plasma CatD for the diagnosis of NASH by using the area 
under the curve (AUC) of plotted receiver-operating characteristic (ROC) curves in the Maastricht cohort. Such a 
statistical analysis in the Maastricht cohort, with a relative small sample size, gives an indication whether plasma 
CatD could be potentially clinical relevant for the non-invasive detection of NASH.
Normal & Steatosis vs. NASH. First, we compared plasma ALT and CatD levels in normal + steatotic subjects vs. 
patients with NASH. The AUC of ALT alone was estimated to be 65%, whereas CatD displayed an AUC of 77% 
(Fig. 4A). Notably, combining both enzymes led to an increase in the AUC from 65% to 77% compared to ALT 
Figure 1. CatD associated with ALT and hepatic inflammation. (A) CatD in plasma of subjects with or 
without hepatic inflammation (n = 127). (B) The Pearson correlation test was used to calculate the correlation 
coefficient (r) between plasma CatD and ALT. *** indicates p < 0.001.
www.nature.com/scientificreports/
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alone (see Supplementary Fig. S1). Thus, the addition of CatD to ALT improved the diagnostic value for distin-
guishing NASH subjects from those who are healthy or have steatosis.
Steatosis vs. NASH. Whereas ALT alone demonstrated low predictive power to discriminate steatosis from 
NASH (AUC: 51%), CatD demonstrated improved the predictive value with an AUC of 84% (Fig. 4B). In com-
parison to CatD alone, similar diagnostic values were obtained when ALT and CatD were combined with an AUC 
value of 84% (see Supplementary Fig. S1). In short, taking plasma CatD into account, the diagnostic prediction 
for NASH became considerably more accurate than by using ALT alone.
Normal vs. NASH. Almost similar AUC values were obtained for ALT and CatD (74% and 73% respectively) for 
the differentiation between NASH from healthy individuals (Fig. 4C). Combining the two enzymes resulted in a 
minor increase of the AUC value to 77% (see Supplementary Fig. S1). The relatively high AUC value of ALT alone 
for the differentiation between NASH and healthy individuals remained roughly equal upon addition of CatD.
Plasma CatD responds to intervention. To test the effect of an intervention on plasma CatD levels, we 
included an additional liver biopsy-proven cohort (i.e. the Kuopio cohort), which was monitored following a 
1 year surgical intervention. Before the start of the surgical intervention, CatD levels were increased in adults 
with NASH compared to adults who did not show signs of hepatic inflammation (normal vs. NASH: p = 0.039) 
(Fig. 5A), herewith confirming our previous data in this manuscript (Figs 1A and 2A). Additionally, when merg-
ing all three individual cohorts (Cleveland, Maastricht and Kuopio cohort) into one single cohort, plasma CatD 
levels remained increased in patients with hepatic inflammation compared to those without hepatic inflammation 
(p = 0.0003) (see Supplementary Fig. S2). Similar to the Maastricht cohort, CatD correlated with total cholesterol 
levels in plasma (Fig. 5B). The absolute difference of plasma CatD was calculated before and after surgical inter-
vention and demonstrated a significant reduction upon intervention of NASH patients compared to intervention 
of their healthy individual controls (p = 0.007) (Fig. 5C). These data suggest for the first time that plasma CatD 
can be used in the clinical follow-up of adult NASH patients.
CatD localization. Additional to plasma CatD measurements, a CatD staining on normal, steatotic and 
NASH livers was performed and revealed that CatD expression in liver is similar between the three groups and is 
mainly located around the pericentral vein (see Supplementary Fig. S3). Next to this, we examined intracellular 
CatD levels and CatD location in more detail. Bone marrow-derived macrophages (BMDMs) were loaded with 
oxidized low-density lipoproteins (oxLDL), i.e. to mimick hyperlipidemia, or with control medium for 24 h. Our 
Figure 2. Lysosomal CatD in human plasma. (A) CatD in plasma of obese patients with a normal liver 
phenotype, steatosis and NASH (n = 47). According to Brunt’s criteria, patients were divided for NASH grade 
(B). Lobular inflammation (C), steatosis (D) and fibrosis (E) were categorized according to Kleiner’s scoring 
system. (F) The Pearson correlation test was used to calculate the correlation coefficient (r) between plasma 
CatD and total cholesterol levels. *Significantly different from normal. * and ** indicate p < 0.05, and 0.01, 
respectively.
www.nature.com/scientificreports/
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data pointed towards an increase of intracellular CatD upon oxLDL loading, compared to control. Additionally, 
CatD was located closer to the plasma membrane in oxLDL-treated BMDMs, compared to control treatment (see 
Supplementary Fig. S4). Additionally, we observed yellow-orange dots in the merged images, which indicates 
that CatD co-localized with lysosomes. Thus, intracellular CatD expression is increased particularly in lysosomes 
during high cholesterol conditions, and is located closer to the plasma membrane.
Figure 3. Human plasma ALT levels. (A) Plasma ALT in obese patients with either a normal, steatotic or 
NASH liver (n = 47). Patients were classified for NASH grade (Brunt’s score) (B), lobular inflammation (C), 
steatosis (D) and fibrosis (E) (Kleiner’s score). (F) The Pearson correlation test was used to calculate the 
correlation coefficient (r) between plasma ALT and total cholesterol levels *Significantly different from normal. 
*, ** and *** indicate p < 0.05, 0.01, and 0.001 respectively.
Figure 4. Diagnostic accuracy of ALT and CatD for predicting NASH. ROC curve analysis was used to 
assess the area under the curve (AUC), the sensitivity and specificity of ALT and CatD in predicting NASH for 
the following comparisons: healthy & steatotic subjects vs. subjects with NASH (A); subjects with steatosis vs. 
NASH (B); and normal vs. NASH subjects (C).
www.nature.com/scientificreports/
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Discussion
The exact mechanisms leading to NASH remain largely unknown. Diagnosing NASH is of critical importance in 
order to prevent further progression into NAFLD-related cirrhosis and end-stage liver disease. Therefore, better 
understanding of the mechanisms that cause progression to NASH is important.
We have recently established a strong association between CatD in pediatric NASH and children without 
hepatic inflammation11. In the current paper, we observed an association between plasma CatD and NASH in 
three biopsy-proven cohorts of adults. Strikingly, whereas we found a decrease of plasma CatD in NASH chil-
dren, we here show an increase of CatD in the plasma of adults with NASH. These findings suggest a difference in 
disease pathology between adult and pediatric NASH. Furthermore, our observations point to plasma CatD as a 
useful non-invasive tool to improve NASH diagnosis in adults.
Under normal conditions, lipoprotein-derived cholesterol is internalized by macrophages and directed to 
the lysosome for further processing. After hydrolysis, free cholesterol is transferred from the lysosome to the 
cytoplasm where the free cholesterol is degraded into bile acid precursors or secreted via cholesterol efflux. The 
difference in pathophysiology between NASH in children and adults could be due to age-dependent changes 
of the lysosomal compartment. Indeed, lysosomal function has previously been shown to be an age-dependent 
process, whereby the amount of lysosomes increase upon ageing27–29. These data suggest that at a young age, the 
amount of lysosomes is low and that, consequently, the cells have difficulties to cope with excessive amounts of 
cholesterol. As such, upon high-cholesterol circumstances, the stability of the lysosomal membrane is likely to 
decrease30, which can eventually lead to lysosomal rupture and subsequent lysosomal enzyme release into the 
cytosol. Lysosomal enzyme secretion into the plasma is hereby prevented and instead, the cytosolic lysosomal 
enzymes activate the apoptotic signaling pathway inducing rapid cell death31. This mechanism could explain the 
reduction of CatD in the plasma of pediatric subjects with NASH compared to subjects without hepatic inflam-
mation11. In contrast to young cells, older cells possess a higher number of lysosomes27–29, suggesting increased 
cholesterol storage capabilities inside the cells. It is therefore likely that adult lysosomes can cope better with 
the cholesterol accumulation and would be less likely to rupture. Nevertheless, cholesterol-filled lysosomes have 
been shown to induce disturbances in the lysosomal enzyme trafficking pathway9,10 that can potentially lead to 
increased levels of lysosomal enzymes in plasma32,33. Likewise, we observed that CatD is increased intracellularly 
during high cholesterol conditions and is located closer to the plasma membrane. Since the plasma membrane is 
the primary site where secretion takes place into plasma34, these data suggest that cholesterol-rich lipoproteins, 
including oxLDL, increases the contact of lysosomes with the plasma and as such leads to elevated levels of 
plasma CatD. This potential mechanism has been illustrated in a schematic figure (see Fig. 6).
Plasma LDL oxidation can be viewed as a representative parameter of oxidative stress that has been shown to 
be induced in healthy elderly compared to young controls, and therefore is strongly associated with the course 
of ageing35,36. In vitro, particularly the intracellular accumulation of the oxidized cholesterol fraction has been 
shown to enhance extracellular secretion of pro-CatD37,38. Immunohistochemical stainings of CatD on human 
liver underlined these findings, as CatD was mainly present in the pericentral area of the liver. Compared to the 
periportal and the midzonal zones, which are relatively nearer to the entering blood supply, the pericentral zone 
receives blood that is lower in oxygen and high in oxidative stress39. As oxidative stress is increased in NASH 
patients40, these data are in line with our observations in plasma, in which increased levels of CatD are asso-
ciated with NASH in adults. Altogether, the observed differences between NASH in children and adults could 
be explained by the fact that secretion of CatD into the plasma is dependent on age-related changes of the lyso-
somes and therefore is dependent on accumulation of specific lipid species. In agreement, several studies indeed 
describe that the histological and pathological characteristics of NASH are age-dependent12–15. Further studies 
are warranted to precisely determine the contribution of lysosomes to NASH disease pathology in children and 
adults.
Figure 5. Plasma CatD levels in the Kuopio cohort. (A) CatD in plasma of obese patients with a normal liver 
phenotype, steatosis and NASH (n = 74). (B) Correlation between CatD and total cholesterol. (C) The absolute 
difference of plasma CatD was calculated before and after one-year of surgical intervention of normal, steatotic 
and NASH subjects.
www.nature.com/scientificreports/
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With the help of lysosomal enzymes, lysosomes are best known for its primary role in protein degradation. 
However, protein degradation during NASH, for example of cholesterol, seems to be disturbed, as we have 
recently established a clear association between hepatic inflammation and increased cholesterol accumulation 
in lysosomes of KCs5. This is underlined by the fact that KCs compromise 15–20% of the total number of liver 
cells41 and account for the main hepatic uptake of modified cholesterol-rich lipoproteins from the circulation42. 
Additionally, numerous studies have shown that lysosomal cholesterol accumulation inside macrophages is an 
event that occurs during inflammation and has been detected in NASH as well as in atherosclerosis5,6. These 
data are in line with previous results showing high cholesterol levels in KCs, as was indicated by numerous 
cholesterol-filled droplets in KCs of livers of NASH adults, while livers of steatotic patients did not show this 
typical foam cell-like phenotype43.
Lysosomal function is not merely restricted to degradation of proteins, such as cholesterol, but increasing evi-
dence now demonstrates that the lysosomal compartment can also be seen as vesicles that can secrete its content, 
for example lysosomal enzymes44,45. Cathepsins, a specific class of lysosomal enzymes, have been shown to be 
significantly involved in mediating the inflammatory response and cholesterol trafficking46–48. Furthermore, we 
have recently reported that plasma CatD was strongly associated with pediatric NASH11. Likewise, a correlation 
exists between CatD and carotid intima-media thickness, an indicator for atherosclerosis49, as well as with a lyso-
somal storage disease50, diseases which both are predominantly characterized by chronic systemic inflammation 
and excessive cholesterol storage inside macrophages. In line, in the current paper, we show that CatD is corre-
lated with histological classifications for NASH as well as with cholesterol. These evidences point to a strong link 
between CatD and cholesterol-mediated inflammation. Therefore, it seems reasonable that lysosomal cholesterol 
accumulation in KCs, and its subsequent effect on lysosomal enzyme homeostasis, is a central mechanism in the 
development of NASH.
Several plasma markers that have been tested as a potential screening method for NASH are in relation to 
apoptosis (cytokeratin-18 (CK-18) fragments)51, inflammation (cytokines and adipokines)52 and advanced gly-
cation end products53. Numerous studies screening NASH patients for individual CK-18 fragments described a 
high diagnostic accuracy with an AUC between 71 and 93%54. Our observations for analyzing CatD individually 
to distinguish NASH from steatotic patients are within the same high accuracy range as CK-18 with an AUC of 
84%. However, whereas CatD correlated with early signs of inflammation, CK-18 represents liver damage and 
fibrosis51. Combining two biomarkers such as total CK-18 with interleukin-6 yielded an AUC of 83% and 84% 
for the combination adiponectin and total CK-1855. In line with this approach, we presented the combination of 
ALT and CatD with a similar high AUC of 84% for separating NASH from steatotic patients. These data suggest 
that including one liver-specific parameter (i.e., ALT) could increase the diagnostic accuracy for detecting a liver 
disease such as NASH. In contrast to ALT, increased CatD levels in the plasma are representative for early-stage 
hepatic inflammation.
Furthermore, we have shown for the first time that plasma CatD responded to a 1-year follow-up period after 
a gastric bypass intervention of NASH patients. Although no follow-up liver biopsies were obtained in the current 
study, gastric bypass intervention has previously been shown to resolve histopathological features of NASH56. 
While plasma CatD responded to the intervention, changes in plasma CK-18 levels following intervention of 
NASH patients have not been defined so far57. Contradictive results have been found concerning plasma transam-
inases after surgical intervention, while others demonstrated a correlation between histological improvement of 
NASH and lower ALT and AST after follow-up58, some did not find a difference postoperatively56. Thus, besides 
Figure 6. Potential mechanism for enhanced plasma CatD levels during adult NASH. In adults, under 
normal conditions, circulating cholesterol-rich lipoproteins are endocytosed and directly distributed to 
the lysosomes. There, lipoprotein-derived cholesteryl esters are further processed following release into the 
cytoplasm. Under conditions with high cholesterol-rich lipoprotein levels, which is commonly associated 
with NASH, Kupffer cells internalize high amounts of lipoproteins, leading to enlarged lysosomes. These large 
cholesterol-filled lysosomes can potentially disturb the trafficking of lysosomes, which can lead to migration of 
the lysosome towards the plasma membrane. Hence, enhanced extracellular secretion of CatD into the plasma 
can occur.
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NASH diagnosis, plasma CatD can potentially be used in the clinical follow-up of NASH. Further trials are nec-
essary to validate the response of plasma CatD upon a surgical intervention.
Thus, in the current study, we have found a strong association between plasma CatD and NASH in adults. In 
contrast to childhood NASH, we now demonstrated elevated CatD levels in plasma of NASH adults. These data 
suggest the existence of a distinct disease pathology between NASH in children and adults. Plasma CatD holds 
potential clinical utility as it correlated with histological characteristics of NASH and regression of this disease. 
Mechanistically, these findings point to the important role of lysosomes in the development of NASH and should 
be further investigated.
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